journal
https://read.qxmd.com/read/38627451/herpes-simplex-virus-reactivation-among-hematopoietic-stem-cell-transplant-recipients-re-evaluating-acyclovir-dosage
#1
LETTER
Nada Alsuhebany, Bashayer Alshehri, Atheer Aldairem, Muneerah M Aleissa, Hajar AlQahtani, Khalid Albarqi, Basil Almotairi, Mohammed AlAmri, Walid Alanazi, Saeed Alay, Bader Alahmari, Mohsen Alzahrani
No abstract text is available yet for this article.
April 16, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38627450/development-and-validation-of-an-automated-computational-approach-to-grade-immune-effector-cell-associated-hematotoxicity
#2
JOURNAL ARTICLE
Emily C Liang, Kai Rejeski, Teng Fei, Aya Albittar, Jennifer J Huang, Andrew J Portuguese, Qian Wu, Sandeep Raj, Marion Subklewe, Roni Shouval, Jordan Gauthier
Hematologic toxicity frequently complicates chimeric antigen receptor (CAR) T-cell therapy, resulting in significant morbidity and mortality. In an effort to standardize reporting, the European Hematology Association (EHA) and European Society of Blood and Marrow Transplantation (EBMT) devised the immune effector cell-associated hematotoxicity (ICAHT) grading system, distinguishing between early (day 0-30) and late (after day +30) events based on neutropenia depth and duration. However, manual implementation of ICAHT grading criteria is time-consuming and susceptible to subjectivity and error...
April 16, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38627449/outcomes-of-allogeneic-haematopoietic-cell-transplantation-for-myelofibrosis-in-children-and-adolescents-the-retrospective-study-of-the-ebmt-paediatric-diseases-wp
#3
JOURNAL ARTICLE
Jacek Wachowiak, Jacques-Emmanuel Galimard, Arnaud Dalissier, Rawad Rihani, Hawazen AlSaedi, Robert F Wynn, Jean-Hugues Dalle, Régis Peffault de Latour, Petr Sedlacek, Adriana Balduzzi, Thomas Schroeder, Ivana Bodova, Marta Gonzalez Vicent, Bernd Gruhn, Rose-Marie Hamladji, Gergely Krivan, Katharine Patrick, Agnieszka Sobkowiak-Sobierajska, Polina Stepensky, Ali Unal, Persis Amrolia, Antonio Perez Martinez, Fanny Rialland, Mahmoud Aljurf, Antonella Isgro, Amos Toren, Marc Bierings, Selim Corbacioglu, Krzysztof Kałwak
This retrospective study evaluated 35 children (median age 5.2 years; range 0.4-18) with myelofibrosis (MF), including 33 with primary myelofibrosis and 2 with secondary myelofibrosis transplanted from matched sibling donor (MSD) (n = 17) or non-MSD (n = 18) between 2000 and 2022. Conditioning was usually chemotherapy-based (n = 33) and myeloablative (n = 32). Fifteen patients received bone marrow (BM), 14 haematopoietic cells (HC) from peripheral blood (PB), and 6 from cord blood (CB)...
April 16, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38627448/ai-in-wine-and-haematology
#4
EDITORIAL
Shaun R McCann
No abstract text is available yet for this article.
April 16, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38615143/post-transplant-cyclophosphamide-calcineurin-inhibitor-and-mycophenolate-mofetil-compared-to-anti-thymocyte-globulin-calcineurin-inhibitor-and-methotrexate-combinations-as-graft-versus-host-disease-prophylaxis-post-allogeneic-stem-cell-transplantation-from
#5
JOURNAL ARTICLE
Arnon Nagler, Myriam Labopin, Ryszard Swoboda, Thomas Schroeder, Rose-Marie Hamladji, Laimonas Griskevicius, Urpu Salmenniemi, Alessandro Rambaldi, Stephan Mielke, Alexander Kulagin, Jakob Passweg, Thomas Luft, Tobias Gedde-Dahl, Edouard Forcade, Grzegorz Helbig, Matthias Stelljes, Cristina Castilla-Llorente, Alexandros Spyridonidis, Eolia Brissot, Fabio Ciceri, Mohamad Mohty
Post-transplant cyclophosphamide plus calcineurin inhibitor (CNI)(tacrolimus or cyclosporine A) plus mycophenolate mofetil (PTCy/TAC or CSA/MMF) and anti-thymocyte globulin plus CNI (tacrolimus or cyclosporine A) plus methotrexate (ATG/TAC or CSA/MTX) are common graft-versus-host disease (GVHD) prophylaxis regimens. We compared the two regimens in patients with acute myeloid leukemia (AML) undergoing allogeneic transplantation from matched siblings or unrelated donors. 402 received PTCy/TAC or CSA/MMF and 5648 received ATG/TAC or CSA/MTX...
April 13, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38615142/safety-and-efficacy-of-a-new-academic-cd19-directed-car-t-cell-for-refractory-relapsed-non-hodgkin-lymphoma-and-acute-lymphoblastic-leukemia-in-brazil
#6
LETTER
Camila D Donadel, Gil C De Santis, Thiago E Gonçalves, Bruno G Pires, Leonardo C Palma, Flavia Gava, Renato Luiz Guerino-Cunha, Joana T B Faria, Gabriela V A Silva, Luiz Guilherme Darrigo-Junior, Giancarlo Fatobene, Vanderson Rocha, Dimas T Covas, Rodrigo T Calado, Diego V Clé
No abstract text is available yet for this article.
April 13, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38615141/busulfan-plus-cyclophosphamide-vs-total-body-irradiation-plus-cyclophosphamide-for-allogeneic-hematopoietic-stem-cell-transplantation-in-patients-with-acute-t-lymphoblastic-leukemia-a-large-scale-propensity-score-matching-based-study
#7
LETTER
Yifan Shen, Minyuan Liu, Danya Shen, Mengqian Chu, Xuekai Li, Xiang Zhang, Yi Fan, Jia Chen, Depei Wu, Shaoyan Hu, Yang Xu
No abstract text is available yet for this article.
April 13, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38605146/efficacy-of-eculizumab-in-transplantation-associated-thrombotic-microangiopathy-results-of-the-french-nationwide-study-on-behalf-of-the-sfgm-tc-and-the-cnr-mat
#8
LETTER
Marion Peyre, Flore Sicre de Fontbrune, Ana Berceanu, Lise Benjemia, Martin Castelle, Maud D'Aveni, Ambroise Marçais, Eleonore Kaphan, Claude-Eric Bulabois, Anne Sirvent, Pierre-Simon Rohrlich, Valerie Coiteux, Sylvain Chantepie, Stéphanie Nguyen-Quoc, Régis Peffault de Latour, Paul Coppo
No abstract text is available yet for this article.
April 11, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38600163/insulin-eye-drops-for-severe-refractory-chronic-ocular-graft-versus-host-disease
#9
LETTER
V Tahmaz, L Menghesha, M E Stern, U Holtick, C Scheid, P Steven
No abstract text is available yet for this article.
April 10, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38600162/post-transplant-cyclophosphamide-at-80%C3%A2-mg-kg-with-low-dose-post-engraftment-anti-thymocyte-globulin-in-haploidentical-transplantation-with-myeloablative-conditioning
#10
JOURNAL ARTICLE
Lining Wang, Guilin Xu, Ling Wang, Jieling Jiang, Wenhui Gao, Ming Wan, Didier Blaise, Jiong Hu
While post-transplant cyclophosphamide (PTCy) is commonly used as graft-versus-host disease (GvHD) prophylaxis in haploidentical stem cell transplantation (haplo-HSCT), its dose remains a matter of debate due to side effect concerns. Standard dose of 100 mg/kg associated with tacrolimus and post-engraftment anti-thymocyte globulin (ATG) was used as the reference GvHD prophylaxis in our center and had demonstrated encouraging results. Though PTCy 80 mg/kg was shown to be feasible in patients in reduced-intensity conditioning, whether it exerts equivalent GvHD prophylactic efficacy in myeloablative conditioning (MAC) setting has not been confirmed...
April 10, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38594510/outcomes-of-haploidentical-bone-marrow-transplantation-in-infant-acute-leukemia-a-single-center-experience
#11
LETTER
Dimitrios Filioglou, Laurel Truscott, Naresh Reddivalla, Emmanuel Katsanis
No abstract text is available yet for this article.
April 9, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38580777/addition-of-ruxolitinib-to-standard-graft-versus-host-disease-prophylaxis-for-allogeneic-stem-cell-transplantation-in-aplastic-anemia-patients
#12
JOURNAL ARTICLE
Xiaoyu Zhang, Xiaoli Zhao, Shulian Chen, Mengze Hao, Lining Zhang, Ming Gong, Yuanyuan Shi, Jialin Wei, Ping Zhang, Sizhou Feng, Yi He, Erlie Jiang, Mingzhe Han
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers rapid hematopoietic and immune reconstitution for aplastic anemia (AA). As a non-malignant disorder, attenuation of GVHD remains a clinical priority in AA patients. Our study sought to investigate the safety and efficacy of the prophylactic use of ruxolitinib in allogeneic HSCT. A total of 35 AA patients were retrospectively consecutively treated with allo-HSCT whereby ruxolitinib was added to the standard GVHD prophylaxis regimen (rux group)...
April 5, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38565964/salvage-haploidentical-transplantation-for-graft-failure-after-first-haploidentical-allogeneic-stem-cell-transplantation-an-updated-experience
#13
JOURNAL ARTICLE
Rui Ma, Dan-Ping Zhu, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Xiao-Dong Mo, Meng Lv, Yuan-Yuan Zhang, Yi-Fei Cheng, Chen-Hua Yan, Yu-Hong Chen, Yao Chen, Jing-Zhi Wang, Feng-Rong Wang, Ting-Ting Han, Jun Kong, Zhi-Dong Wang, Wei Han, Huan Chen, Ying-Jun Chang, Yun He, Zheng-Li Xu, Feng-Mei Zheng, Hai-Xia Fu, Kai-Yan Liu, Xiao-Jun Huang, Yu-Qian Sun
Graft failure is a fatal complication following allogeneic stem cell transplantation where a second transplantation is usually required for salvage. However, there are no recommended regimens for second transplantations for graft failure, especially in the haploidentical transplant setting. We recently reported encouraging outcomes using a novel method (haploidentical transplantation from a different donor after conditioning with fludarabine and cyclophosphamide). Herein, we report updated outcomes in 30 patients using this method...
April 2, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38555412/allogeneic-hematopoietic-cell-transplantation-for-older-patients-with-aml-with-active-disease-a-study-from-the-acute-leukemia-working-party-of-the-european-society-for-blood-and-marrow-transplantation-ebmt
#14
JOURNAL ARTICLE
Enrico Maffini, Myriam Labopin, Nicolaus Kröger, Jürgen Finke, Matthias Stelljes, Thomas Schroeder, Herman Einsele, Johanna Tischer, Martin Bornhäuser, Wolfgang Bethge, Arne Brecht, Wolf Rösler, Peter Dreger, Kerstin Schäfer-Eckart, Jakob Passweg, Igor Wolfgang Blau, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
Older adults with acute myeloid leukemia (AML) refractory to initial or reinduction chemotherapy have a dismal prognosis if they do not undergo hematopoietic stem-cell transplantation (HCT). However, data assessing HCT outcomes from different donors are scarce. We evaluated results from a retrospective analysis on patients aged ≥70 years, with AML not in remission who received an allogeneic HCT from HLA-matched sibling donor (MSD), HLA-10/10 matched unrelated donor (MUD), or T-cell replete haploidentical (Haplo) donor, from 2010 to 2021, reported to the ALWP-EBMT database...
March 30, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38538726/a-phase-1-dose-escalation-study-of-low-dose-lenalidomide-maintenance-post-allogeneic-stem-cell-transplantation-for-high-risk-acute-myeloid-leukaemia-or-myelodysplastic-syndrome
#15
LETTER
Ray Mun Koo, Eric Wong, Joanne E Davis, Travis Perera, Andrew Lim, Rachel M Koldej, David S Ritchie
No abstract text is available yet for this article.
March 27, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38521886/improving-the-easix-predictive-power-for-nrm-in-adults-undergoing-allogeneic-hematopoietic-cell-transplantation
#16
LETTER
Silvia Escribano-Serrat, Luis Gerardo Rodríguez-Lobato, María Suárez-Lledó, Alexandra Pedraza, Paola Charry, Joan Cid, Miquel Lozano, Jordi Esteve, Laura Rosiñol, Francesc Fernández-Avilés, Enric Carreras, Maribel Díaz-Ricart, Carmen Martínez, Montserrat Rovira, María Queralt Salas
No abstract text is available yet for this article.
March 23, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38521885/easix-and-cardiac-adverse-events-after-allogeneic-hematopoietic-cell-transplantation
#17
JOURNAL ARTICLE
Carles Tolosa-Ridao, Enric Cascos, Luis Gerardo Rodríguez-Lobato, Alexandra Pedraza, María Suárez-Lledó, Paola Charry, María Teresa Solano, Julia Martinez-Sanchez, Joan Cid, Miquel Lozano, Laura Rosiñol, Jordi Esteve, Álvaro Urbano-Ispizua, Francesc Fernández-Avilés, Carmen Martínez, Enric Carreras, Maribel Díaz-Ricart, Montserrat Rovira, María Queralt Salas
This study investigates the interaction between endothelial activation, indirectly measured using EASIX, and the probability of presenting cardiac adverse events (CAE) during the first year after allo-HCT. The 437 consecutive adults undergoing PB allo-HCT from 2012 and 2021 were included. EASIX was retrospectively calculated before and during the first 6 months after allo-HCT and transformed to log2-base to conduct the statistical analysis. The median age was 53, 46 (10.5%) patients had previous history of cardiac disease, MAC allo-HCTs were performed in 186 (42...
March 23, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38514814/storage-of-wine-and-blood
#18
EDITORIAL
Shaun R McCann
No abstract text is available yet for this article.
March 21, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38514813/transplantation-for-myelofibrosis-patients-in-the-ruxolitinib-era-a-registry-study-from-the-soci%C3%A3-t%C3%A3-francophone-de-greffe-de-moelle-et-de-th%C3%A3-rapie-cellulaire
#19
JOURNAL ARTICLE
Sara Villar, Sylvie Chevret, Xavier Poire, Magalie Joris, Patrice Chevallier, Jean-Henri Bourhis, Edouard Forcade, Sylvain Chantepie, David Beauvais, Nicole Raus, Jacques-Olivier Bay, Michael Loschi, Raynier Devillier, Remy Duléry, Patrice Ceballos, Marie Thérèse Rubio, Sophie Servais, Stephanie Nguyen, Marie Robin
In this SFGM-TC registry study, we report the results after stem cell transplantation (HSCT) in 305 myelofibrosis patients, in order to determine potential risk factors associated with outcomes, especially regarding previous treatment with ruxolitinib. A total of 102 patients were transplanted from an HLA-matched-sibling donor (MSD), and 143 patients received ruxolitinib. In contrast with previous studies, our results showed significantly worse outcomes for ruxolitinib patients regarding overall survival (OS) and non-relapse mortality (NRM), especially in the context of unrelated donors (URD)...
March 21, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38509196/improving-nutritional-status-after-allogeneic-stem-cell-transplantation-results-of-phase-2-allonut-clinical-trial
#20
JOURNAL ARTICLE
Sophie Estran, Michael Loschi, Sami Benachour, Alizée Soldati, Edmond Chiche, Rinzine Sammut, Guillaume Robert, Arnaud Jacquel, Jacques Chibois, Stephane Schneider, Thomas Cluzeau
Malnutrition increases the risk of non-relapse mortality after allogeneic stem cell transplantation (aHSCT). Here are the results of the ALLONUT clinical trial designed to improve the nutritional outcome of patients receiving aHSCT. ALLONUT is a prospective open label phase 2 clinical trial assessing the efficacy of a close tailored nutritional support and management with traditional and original solutions to improve patients nutritional status following aHSCT. Nutritional status evaluation was performed before transplantation, on Day 0, 30, 100 and one year after transplantation...
March 20, 2024: Bone Marrow Transplantation
journal
journal
20054
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.